González-Antuña Ana, Rodríguez-González Pablo, Ohlendorf Rudiger, Henrion André, Delatour Vincent, García Alonso J Ignacio
Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, Julián Clavería 8, 33006 Oviedo, Spain.
Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, Julián Clavería 8, 33006 Oviedo, Spain.
J Proteomics. 2015 Jan 1;112:141-55. doi: 10.1016/j.jprot.2014.09.005. Epub 2014 Sep 16.
We propose a peptide-based isotope dilution mass spectrometry approach for Cystatin C determination in human serum samples, a clinical marker for renal status for which backup by a mass spectrometry based primary method has been missing so far. In contrast to common protocols, the isotope labelled version of the proteotypic signature peptide is designed such as keeping the isotopic difference as little as possible with respect to the peptide released from the protein. Peptides labelled in two (13)C atoms are added to the serum samples just before proteolysis. After two steps of chromatographic purification the sample is measured by selected reaction monitoring using a LC-MS/MS. Resolution of the first quadrupole is reduced to transmit the whole parent ion cluster to the collision cell for monitoring accurate isotopic distributions of the molecular fragments. Molar fractions of labelled and natural abundance peptides are directly obtained from the experimental mass spectra of the in-cell fragment ions. Thus, the natural abundance protein concentration is obtained from the fragment-ion spectrum of the sample without resorting to extra calibration runs. Applicability of the approach is demonstrated by the measurement of the serum concentration of Cystatin C in Reference Material ERM R-DA471/IFCC and real samples.
Cystatin C is used as an alternative marker instead of, or in combination with creatinine for non-invasive determination of glomerular filtration rates. Advantages advocating in favour of Cystatin C in diagnosis of chronic kidney diseases are the lower variability of its serum level and, particularly, virtual independence on sex, age and muscle mass. However, in order to capitalize, accuracy of measurement has to be in proportion with the predictive power of the marker. Though there are label-free methods available for screening purposes or high-throughput analysis, achieving high levels of reliability and accuracy in quantitative proteomics takes reference to isotope labelled materials. Present routine assays (mainly nephelometry, turbidimetry and ligand-binding assays) are known to leave improvement to be desired in that respect. Absolute quantification based on enzymatic signature-peptides provides a method principle establishing traceability to the International System of Units on the level of primary methods. The kind of technique is capable, by this way, of high accuracy value-assignment to matrix materials needed for calibration of present routine assays, where not completely replacing them. Cystatin C measurement by isotope dilution mass spectrometry is developed in this study with the aim of making available this tool to support diagnostics of kidney function in the same way.
我们提出了一种基于肽的同位素稀释质谱法,用于测定人血清样本中的胱抑素C,胱抑素C是一种肾脏状态的临床标志物,目前尚缺乏基于质谱的主要方法作为支持。与常规方案不同,蛋白型特征肽的同位素标记版本设计为使其与从蛋白质释放的肽的同位素差异尽可能小。在蛋白水解前,将标记有两个(13)C原子的肽添加到血清样本中。经过两步色谱纯化后,使用液相色谱-串联质谱通过选择反应监测对样品进行测量。降低第一四极杆的分辨率,以将整个母离子簇传输到碰撞池,用于监测分子片段的准确同位素分布。标记肽和天然丰度肽的摩尔分数直接从细胞内碎片离子的实验质谱图中获得。因此,无需进行额外的校准运行,即可从样品的碎片离子光谱中获得天然丰度的蛋白质浓度。通过测量参考物质ERM R-DA471/IFCC和实际样品中的胱抑素C血清浓度,证明了该方法的适用性。
胱抑素C用作替代标志物,单独或与肌酐联合用于无创测定肾小球滤过率。在慢性肾脏病诊断中支持使用胱抑素C的优点包括其血清水平变异性较低,特别是几乎不受性别、年龄和肌肉量的影响。然而,为了充分利用其优势,测量的准确性必须与该标志物的预测能力相称。虽然有用于筛查目的或高通量分析的无标记方法,但在定量蛋白质组学中实现高水平的可靠性和准确性需要参考同位素标记材料。目前的常规检测方法(主要是比浊法、比浊法和配体结合法)在这方面仍有待改进。基于酶促特征肽的绝对定量提供了一种方法原理,可在主要方法层面建立与国际单位制的溯源性。通过这种方式,这种技术能够对当前常规检测方法校准所需的基质材料进行高精度赋值,而不是完全取代它们。本研究开发了通过同位素稀释质谱法测量胱抑素C的方法,目的是提供这一工具,以同样的方式支持肾功能诊断。